Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949052 · ClinicalTrials.gov registry record
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 1,000
- Enrollment target
NCT00949052 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 1,000 participants.
The verdict
NCT00949052 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- OTHER questionnaire administration
- GENETIC DNA analysis
- GENETIC polymorphism analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2009-01 |
| Est. Completion | 2018-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949052
The ClinicalTrials.gov registry entry for NCT00949052 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00949052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949052 about?
NCT00949052 is a clinical study titled "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer". RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
What is the current status of trial NCT00949052?
This trial is currently terminated. The enrollment target is 1,000 participants. The study started on 2009-01. Estimated completion is 2018-02.
What interventions are being tested in trial NCT00949052?
The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), questionnaire administration (OTHER), DNA analysis (GENETIC), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00949052?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.